Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P62847
UPID:
RS24_HUMAN
Alternative names:
40S ribosomal protein S24
Alternative UPACC:
P62847; E7EPK6; P16632; Q5T0P7; Q5T0P8; Q7Z3D1
Background:
Small ribosomal subunit protein eS24, also known as 40S ribosomal protein S24, plays a crucial role in protein synthesis. It is a component of the small ribosomal subunit, essential for processing pre-rRNA and maturing 40S ribosomal subunits. This protein is involved in the intricate process of ribosome assembly within the nucleolus, facilitating RNA folding, modifications, and cleavage.
Therapeutic significance:
Small ribosomal subunit protein eS24 is linked to Diamond-Blackfan anemia 3, a condition characterized by hypoplastic anemia and increased leukemia risk. Understanding the role of Small ribosomal subunit protein eS24 could open doors to potential therapeutic strategies for this congenital anomaly.